BRIM Biotechnology Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing B… Read more
BRIM Biotechnology Inc. (6885) - Net Assets
Latest net assets as of June 2024: NT$1.62 Billion TWD
Based on the latest financial reports, BRIM Biotechnology Inc. (6885) has net assets worth NT$1.62 Billion TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.64 Billion) and total liabilities (NT$25.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.62 Billion |
| % of Total Assets | 98.47% |
| Annual Growth Rate | 41.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 54.74 |
BRIM Biotechnology Inc. - Net Assets Trend (2019–2023)
This chart illustrates how BRIM Biotechnology Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BRIM Biotechnology Inc. (2019–2023)
The table below shows the annual net assets of BRIM Biotechnology Inc. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.74 Billion | +89.85% |
| 2022-12-31 | NT$914.69 Million | +91.40% |
| 2021-12-31 | NT$477.89 Million | +81.14% |
| 2020-12-31 | NT$263.82 Million | -38.62% |
| 2019-12-31 | NT$429.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BRIM Biotechnology Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 59568900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.16 Billion | 66.66% |
| Other Comprehensive Income | NT$173.55 Million | 9.99% |
| Other Components | NT$1.55 Billion | 89.53% |
| Total Equity | NT$1.74 Billion | 100.00% |
BRIM Biotechnology Inc. Competitors by Market Cap
The table below lists competitors of BRIM Biotechnology Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lechwerke AG
F:LEC
|
$87.57 Million |
|
Smartbroker Holding AG
XETRA:SB1
|
$87.57 Million |
|
RENOLD PLC LS-05
F:7M5
|
$87.58 Million |
|
Anderson Industrial Corp
TW:1528
|
$87.63 Million |
|
Safkar Ege Sogutmacilik Klima Soguk Hava Tesisleri Ihracat Ithalat Sanayi ve Tic
IS:SAFKR
|
$87.53 Million |
|
A.L.A. S.P.A. O.N.
F:8WD
|
$87.49 Million |
|
Prairie Operating Co. Common Stock
OTCQB:PROP
|
$87.48 Million |
|
NAFCO CO. LTD.
F:64E
|
$87.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BRIM Biotechnology Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 914,692,000 to 1,736,513,000, a change of 821,821,000 (89.8%).
- Net loss of 688,022,000 reduced equity.
- Other comprehensive income increased equity by 9,924,000.
- Other factors increased equity by 1,499,919,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-688.02 Million | -39.62% |
| Other Comprehensive Income | NT$9.92 Million | +0.57% |
| Other Changes | NT$1.50 Billion | +86.38% |
| Total Change | NT$- | 89.85% |
Book Value vs Market Value Analysis
This analysis compares BRIM Biotechnology Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.06x to 1.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$5.90 | NT$29.85 | x |
| 2020-12-31 | NT$4.00 | NT$29.85 | x |
| 2021-12-31 | NT$7.79 | NT$29.85 | x |
| 2022-12-31 | NT$12.40 | NT$29.85 | x |
| 2023-12-31 | NT$17.27 | NT$29.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BRIM Biotechnology Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -764468.89%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-39.62%) is below the historical average (-31.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -34.23% | 0.00% | 0.00x | 1.28x | NT$-153.47 Million |
| 2020 | -33.33% | -96.89% | 0.29x | 1.20x | NT$-114.32 Million |
| 2021 | -22.07% | -29291.39% | 0.00x | 1.04x | NT$-153.24 Million |
| 2022 | -29.99% | -52143.92% | 0.00x | 1.03x | NT$-365.75 Million |
| 2023 | -39.62% | -764468.89% | 0.00x | 1.02x | NT$-861.67 Million |
Industry Comparison
This section compares BRIM Biotechnology Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BRIM Biotechnology Inc. (6885) | NT$1.62 Billion | -34.23% | 0.02x | $87.55 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |